GlassScriptPhysician profile
Ronald M Mcfarland
NPI 1083604391
$432.56
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $64.07 · 2021: $73.85 · 2022: $65.62 · 2023: $14.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $40.96 | 2019 | |
| Allergan, INC. | $39.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.82 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.85 | 2021-2022 | |
| Medtronic Vascular, INC. | $27.30 | 2019-2020 | |
| Amgen INC. | $26.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.90 | 2019 | |
| Glaxosmithkline, LLC. | $18.33 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.23 | 2022 | |
| Genentech USA, INC. | $15.59 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.46 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.93 | 2021 | |
| Novo Nordisk INC | $14.85 | 2023 | |
| Circassia INC. | $14.07 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.29 | 2019 | |
| Phadia US INC. | $12.34 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.87 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mcfarland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.